 |
|
|
|
 |
|
|
| Article 1 to 3 out of 3 concerning Xenova Group plc
|
-
Xenova Group plc with Successful Results from Second Clinical Trial of Anti-Smoking Vaccine, TA-NIC
(07/15/2004)
Slough, UK. Xenova Group plc announced initial results from the second clinical trial of TA-NIC, the Company's therapeutic vaccine being developed for the treatment of nicotine addiction.60 smokers, divided into three cohorts of 20 subjects, have ...
-
Xenova Group plc: Positive Results from TA-CD Cocaine Vaccine Trial Presented at CPDD Meeting
(06/15/2004)
Slough, UK. Xenova Group plc announced the presentation of results of two dose escalation Phase II studies of TA-CD, a vaccine being developed for the treatment of cocaine addiction, at the College on Problems of Drug Dependence 66th Annual ...
-
Xenova Group plc: Development and Licence Agreement with Genentech Inc for Novel Drugs in Immune Inf
(04/25/2002)
Slough, UK, 23 April, 2002 - Xenova Group plc today announces that it has signed an exclusive development and licence agreement with South San Francisco-based Genentech Inc worth up to US$63m plus royalties. The agreement provides Genentech with ...
Additional information
Xenova Group plc
Slough, United Kingdom
Company
|
|
|
|
|
|
Top
